PART I [Business](index=4&type=section&id=Item%201.%20Business) Organogenesis develops, manufactures, and commercializes regenerative medicine products for Advanced Wound Care and Surgical & Sports Medicine, achieving **$338.3 million** in 2020 revenue - Organogenesis operates in two primary markets: Advanced Wound Care and Surgical & Sports Medicine, offering a portfolio of regenerative medicine products[17](index=17&type=chunk) Fiscal Year 2020 Financial Highlights | Metric | Value (in millions USD) | | :--- | :--- | | **Revenue** | $338.3 | | **Operating Expenses** | $223.6 | - The company's strategy includes driving deeper penetration in the Advanced Wound Care market, expanding into the Surgical & Sports Medicine market, launching new pipeline products, and expanding its sales force[26](index=26&type=chunk) [Industry Overview](index=7&type=section&id=Item%201.%20Business-Industry%20Overview) The company operates in the **$14.9 billion** Advanced Wound Care and Surgical & Sports Medicine markets, driven by an aging population and comorbidities - The total addressable market for the company's products in Advanced Wound Care and Surgical & Sports Medicine was estimated at **$14.9 billion** in 2018[29](index=29&type=chunk) - The skin substitute market, a key segment for Organogenesis, is significantly underpenetrated, with less than **5%** of the **3.3 million** difficult-to-heal wounds in the U.S. being treated with skin substitutes annually[44](index=44&type=chunk) - The immediate addressable Surgical & Sports Medicine market for the company's products is estimated at approximately **$6.1 billion**, with an expected **CAGR of 8%**, driven by an increase in spinal fusions, bone reconstruction, and musculoskeletal injuries[49](index=49&type=chunk) [Our Products](index=11&type=section&id=Item%201.%20Business-Our%20Products) The company offers a comprehensive product suite for Advanced Wound Care and Surgical & Sports Medicine, including bioengineered therapies and amniotic tissues Advanced Wound Care Product Portfolio | Product | Description | Regulatory Pathway | Clinical Application | | :--- | :--- | :--- | :--- | | **Affinity** | Fresh amniotic membrane wound covering | 361 HCT/P | Chronic and acute wounds | | **Apligraf** | Bioengineered living cell therapy | PMA | VLUs; DFUs | | **Dermagraft** | Bioengineered product with living human fibroblasts | PMA | DFUs | | **NuShield** | Dehydrated placental tissue wound covering | 361 HCT/P | Chronic and acute wounds | | **PuraPly AM** | Antimicrobial barrier with purified native collagen matrix | 510(k) | Chronic and acute wounds | - The company plans to suspend manufacturing of Dermagraft in Q4 2021 and sales in Q1 2022 to consolidate manufacturing in Massachusetts, expecting substantial long-term cost savings without a material impact on net revenue[66](index=66&type=chunk) Surgical & Sports Medicine Product Portfolio | Product | Description | Regulatory Pathway | Clinical Application | | :--- | :--- | :--- | :--- | | **Affinity** | Fresh amniotic membrane barrier | 361 HCT/P | Barrier membrane for soft tissue repair | | **NuCel** | Cellular suspension from amniotic fluid/tissue | 361 HCT/P* | Orthopedic surgical procedures (e.g., bony fusion) | | **NuShield** | Dehydrated placental tissue barrier | 361 HCT/P | Barrier membrane for soft tissue repair | | **PuraPly AM** | Purified native collagen matrix with PHMB | 510(k) | Antimicrobial barrier for open surgical wounds | | **ReNu** | Cryopreserved suspension of amniotic fluid cells/tissue | 361 HCT/P* | Chronic inflammatory conditions (e.g., knee osteoarthritis) | *May require BLA approval per recent FDA guidance [Clinical Studies and Product Pipeline](index=15&type=section&id=Item%201.%20Business-Clinical%20Studies%20and%20Product%20Pipeline) The company conducts clinical studies to validate product efficacy and value, with a pipeline including PuraForce, PuraPly XT, Novachor, and TransCyte - The company has **six** ongoing studies for its Advanced Wound Care and Surgical & Sports Medicine products to generate clinical data, which is expected to enhance sales and reimbursement dynamics[76](index=76&type=chunk) - A pivotal Phase 3 study for ReNu is underway to evaluate its efficacy in treating Knee Osteoarthritis, with completion estimated for Q5 2023[79](index=79&type=chunk) - The product pipeline includes the planned re-introduction of TransCyte, a PMA-approved product for deep second- and third-degree burns, with a full commercial launch targeted for late 2023[114](index=114&type=chunk) [Commercial Infrastructure, Manufacturing, and Reimbursement](index=24&type=section&id=Item%201.%20Business-Commercial%20Infrastructure%2C%20Manufacturing%2C%20and%20Reimbursement) The company leverages a direct sales force and independent agencies, manages in-house and outsourced manufacturing, and relies on complex third-party reimbursement - As of December 31, 2020, the company's commercial team consisted of approximately **300** direct sales representatives and **175** independent agencies[116](index=116&type=chunk) - Production of the Affinity product was suspended in Q1 2019 due to supplier issues and resumed commercial-scale production in Q2 2020 after identifying an alternate supplier[124](index=124&type=chunk) - PuraPly AM and PuraPly's Medicare pass-through payment status expired on September 30, 2020, with payment now bundled into the application procedure rate as of October 1, 2020[131](index=131&type=chunk)[136](index=136&type=chunk) [Government Regulation](index=29&type=section&id=Item%201.%20Business-Government%20Regulation) The company's products are subject to extensive FDA regulation across various pathways, including 510(k), PMA, BLA, and HCT/P, alongside anti-kickback and false claims laws - The company's products are regulated through multiple FDA pathways: **510(k)** clearance (PuraPly), **PMA** approval (Apligraf, Dermagraft), and potentially **BLA** approval[153](index=153&type=chunk)[154](index=154&type=chunk) - Certain products like Affinity and NuShield are regulated as Section 361 HCT/Ps, exempting them from premarket review, though the FDA could challenge this classification[161](index=161&type=chunk) - In January 2021, ReNu received the Regenerative Medicine Advanced Therapy (**RMAT**) designation from the FDA for the management of symptoms associated with knee osteoarthritis[171](index=171&type=chunk) - The company is subject to federal and state fraud and abuse laws, including the Anti-Kickback Statute, with a previous Dermagraft owner settling False Claims Act allegations for **$350 million** related to kickbacks[179](index=179&type=chunk) [Risk Factors](index=35&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks from fluctuating results, internal control weaknesses, intense competition, regulatory reclassification of products, supply chain issues, and substantial indebtedness - The company has identified a **material weakness** in its internal control over financial reporting due to a lack of formal accounting policies, procedures, and controls, persisting as of December 31, 2020[192](index=192&type=chunk)[196](index=196&type=chunk)[199](index=199&type=chunk) - A key risk is the potential for the FDA to determine that HCT/P products like Affinity, NuCel, and ReNu do not qualify for regulation solely under Section 361 of the PHSA, which would require costly **BLA** or **PMA** approvals and could force a suspension of sales[192](index=192&type=chunk)[260](index=260&type=chunk) - The company is dependent on a limited group of suppliers, as evidenced by the **over one-year suspension** of Affinity production due to sole supplier issues, impacting revenue[209](index=209&type=chunk)[212](index=212&type=chunk) - The company is a "controlled company" under Nasdaq rules, exempting it from certain corporate governance requirements due to majority voting power held by "Controlling Entities"[192](index=192&type=chunk)[331](index=331&type=chunk) [Properties](index=71&type=section&id=Item%202.%20Properties) The company operates from leased facilities, including its Canton, MA headquarters and other sites in Massachusetts, California, and Alabama, with some leases expiring soon - The main corporate headquarters in Canton, MA, is leased from entities controlled by individuals who also control a majority of the company's voting stock[373](index=373&type=chunk) - The company is consolidating its La Jolla, CA operations, with the current lease expiring at the end of 2021, and has entered into a new **10-year lease** for a smaller facility in San Diego, CA[375](index=375&type=chunk) [Legal Proceedings](index=71&type=section&id=Item%203.%20Legal%20Proceedings) The company is not currently involved in any material legal proceedings, with no expected material adverse effects from ordinary course litigation - The company reports no material legal proceedings as of the filing date[377](index=377&type=chunk) PART II [Market For Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=72&type=section&id=Item%205.%20Market%20For%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's Class A common stock trades on Nasdaq under ORGO, with no cash dividends paid or planned due to credit agreement restrictions - The company's Class A Common Stock trades on the NASDAQ Capital Market under the ticker **ORGO**[380](index=380&type=chunk) - The company has never paid cash dividends and does not anticipate doing so in the foreseeable future, partly due to restrictions in its 2019 Credit Agreement[381](index=381&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=73&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) The company achieved **$338.3 million** in 2020 net revenue, a **30%** increase, turning a **$40.5 million** net loss into a **$17.9 million** net income Financial Performance (2018-2020) | Metric (in millions USD) | 2020 | 2019 | 2018 | | :--- | :--- | :--- | :--- | | **Net Revenue** | $338.3 | $261.0 | $193.4 | | **Gross Profit** | $251.0 | $185.0 | $124.6 | | **Gross Margin** | 74% | 71% | 64% | | **Income (Loss) from Operations** | $27.4 | $(29.5) | $(51.6) | | **Net Income (Loss)** | $17.9 | $(40.5) | $(64.8) | | **Adjusted EBITDA** | $36.9 | $(18.2) | $(36.2) | - The **30%** year-over-year revenue growth in 2020 was driven by a **33%** increase in the Advanced Wound Care segment and a **9%** increase in the Surgical & Sports Medicine segment[420](index=420&type=chunk)[421](index=421&type=chunk) - The company's PuraPly products had Medicare pass-through reimbursement status from October 1, 2018, through September 30, 2020, with its expiration potentially impacting future revenue[403](index=403&type=chunk) [Liquidity and Capital Resources](index=82&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations-Liquidity%20and%20Capital%20Resources) As of December 31, 2020, the company held **$84.4 million** in cash, with **$84.8 million** in total debt, and generated **$6.8 million** in operating cash flow Cash and Debt Position (Year-End) | (in thousands USD) | 2020 | 2019 | | :--- | :--- | :--- | | **Cash** | $84,394 | $60,174 | | **Total Debt** | $84,771 | $100,606 | Cash Flow Summary (Year Ended Dec 31) | (in thousands USD) | 2020 | 2019 | | :--- | :--- | :--- | | **Net cash from operating activities** | $6,801 | $(33,528) | | **Net cash used in investing activities** | $(24,833) | $(6,234) | | **Net cash from financing activities** | $42,468 | $78,727 | - The company's 2019 Credit Agreement requires compliance with financial covenants, including minimum revenue thresholds, with which the company was in compliance as of December 31, 2020[459](index=459&type=chunk)[460](index=460&type=chunk) [Critical Accounting Policies](index=85&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations-Critical%20Accounting%20Policies) Critical accounting policies involve significant judgments in revenue recognition, asset valuation, goodwill impairment, income taxes, and contingent earnout liabilities - Revenue is recognized when a customer obtains control of the product, net of estimated reserves for returns, discounts, and GPO rebates based on historical experience[469](index=469&type=chunk) - Goodwill is tested for impairment annually at the consolidated level, with no impairments recorded in 2020, 2019, or 2018[473](index=473&type=chunk)[477](index=477&type=chunk) - Due to a three-year cumulative loss position through December 31, 2020, the company maintains a full valuation allowance against its net deferred tax assets[481](index=481&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=88&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks are interest rate fluctuations on its **$70.0 million** variable-rate debt and minimal foreign currency exchange variability - The company is exposed to interest rate risk from **$70.0 million** in variable-rate borrowings under its 2019 Credit Agreement as of December 31, 2020[490](index=490&type=chunk) - Foreign currency risk is deemed not material as most business is conducted in the U.S. and the Swiss subsidiary uses the U.S. dollar as its functional currency[491](index=491&type=chunk) [Financial Statements and Supplementary Data](index=88&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the company's audited consolidated financial statements for 2018-2020, including balance sheets, statements of operations, equity, and cash flows [Note 3. Acquisition](index=112&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data-Note%203.%20Acquisition) On September 17, 2020, the company acquired CPN Biosciences for **$19.0 million**, recognizing **$13.6 million** in intangible assets and **$3.2 million** in goodwill CPN Biosciences Acquisition Consideration (Sept 17, 2020) | Consideration Component | Value (in thousands USD) | | :--- | :--- | | Cash | $6,427 | | Class A Common Stock | $8,815 | | Contingent Consideration (Earnout) | $3,782 | | **Total Consideration** | **$19,024** | - The acquisition resulted in **$3.2 million** of goodwill and **$13.6 million** of intangible assets, primarily customer relationships (**$10.7 million**) and developed technologies (**$2.1 million**)[612](index=612&type=chunk) [Note 11. Restructuring](index=116&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data-Note%2011.%20Restructuring) In October 2020, the company initiated a restructuring to consolidate manufacturing, expecting a **$5.5 million** charge by year-end 2021 - The company began a restructuring plan in Q4 2020 to consolidate California manufacturing into Massachusetts, expecting to complete it by year-end 2021[630](index=630&type=chunk) - The total expected restructuring charge is approximately **$5.5 million**, with **$4.5 million** for employee retention benefits and **$1.0 million** for facility closures[630](index=630&type=chunk) [Note 13. Long-Term Debt Obligations](index=117&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data-Note%2013.%20Long-Term%20Debt%20Obligations) The company's primary debt is the 2019 Credit Agreement, with **$70.0 million** outstanding as of December 31, 2020, including a term loan and revolving facility Outstanding Debt as of Dec 31, 2020 | Facility | Outstanding Principal (in thousands USD) | | :--- | :--- | | Line of credit (Revolving Facility) | $10,000 | | Term loan | $60,000 | | **Total** | **$70,000** | - The Term Loan Facility requires interest-only payments through February 2021, followed by **36** equal monthly principal and interest installments, maturing on March 1, 2024[638](index=638&type=chunk) [Note 14. Stockholders' Equity](index=118&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data-Note%2014.%20Stockholders%27%20Equity) As of December 31, 2020, the company had **127.7 million** Class A common shares outstanding, following a **$64.7 million** public offering in November 2020 - In November 2020, the company raised gross proceeds of **$64.7 million** through a public offering of **19.9 million** shares of Class A common stock[661](index=661&type=chunk)[663](index=663&type=chunk) - During Q3 2019, the company exchanged all outstanding public and private placement warrants for approximately **3.3 million** shares of Class A common stock, eliminating all warrants[656](index=656&type=chunk)[658](index=658&type=chunk) [Controls and Procedures](index=89&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that disclosure controls were ineffective as of December 31, 2020, due to a material weakness in internal control over financial reporting - Management concluded that disclosure controls and procedures were not effective as of December 31, 2020[494](index=494&type=chunk) - A **material weakness** in internal control over financial reporting persists, related to the lack of formal accounting policies, procedures, and controls, including proper segregation of duties[497](index=497&type=chunk) - Remediation efforts include implementing a new company-wide **ERP** system, anticipated to go live in the first half of 2021[503](index=503&type=chunk) PART III [Directors, Executive Officers, Corporate Governance, Compensation, and Related Transactions](index=91&type=section&id=Items%2010-14) Information for Items 10-14, covering governance, compensation, and related transactions, is incorporated by reference from the forthcoming Proxy Statement - Information for Items 10, 11, 12, 13, and 14 is incorporated by reference from the company's forthcoming Proxy Statement[505](index=505&type=chunk)[506](index=506&type=chunk)[507](index=507&type=chunk)[508](index=508&type=chunk)[509](index=509&type=chunk) PART IV [Exhibits and Financial Statement Schedules](index=92&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section provides an index of all exhibits filed with the Form 10-K, including financial statements, material agreements, and corporate governance documents - This section provides an index of all exhibits filed with the Form 10-K, including material agreements and corporate governance documents[512](index=512&type=chunk)[513](index=513&type=chunk)

Organogenesis Holdings Inc. (NASDAQ:ORGO) Q3 2020 Results Conference Call November 9, 2020 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Director Henry Hagopian - Interim Chief Financial Officer Conference Call Participants Vik Malhotra - Credit Suisse Ryan Zimmerman - BTIG Steven Lichtman - Oppenheimer & Company Operator Good afternoon, ladies and gentlemen, and welcome to the Third Quarter 2020 Earnings Conference Call for Organogenesis Holdings Inc. At this time, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 98-1329150 (State or other jurisdiction of ...

Organogenesis Holdings, Inc. (NASDAQ:ORGO) Q2 2020 Earnings Conference Call August 10, 2020 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Director Timothy Cunningham - Chief Financial Officer Conference Call Participants Matthew Miksic - Crédit Suisse Ryan Zimmerman - BTIG Richard Newitter - SVB Leerink Steven Lichtman - Oppenheimer Operator Good afternoon, ladies and gentlemen, and welcome to the Second Quarter 2020 Earnings Conference Call for Organogenesis Holding ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 98-1329150 (State or other jurisdiction of inco ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2020 was $61.7 million, an increase of 8% from $57.1 million in Q1 2019 [18] - Gross profit for Q1 2020 was $42.9 million, up 7% from $40.1 million in Q1 2019, with a gross profit margin of 69.6% compared to 70.3% in the prior year [23] - Operating loss for Q1 2020 was $15.1 million, compared to a loss of $12.1 million in Q1 2019, reflecting a 24% increase in losses [30] - Net loss for Q1 2020 was $16.3 million or $0.16 per share, compared to a net loss of $15.7 million or $0.17 per share in Q1 2019 [32] Business Line Data and Key Metrics Changes - Revenue from Advanced Wound Care products was $51.3 million, a 7% increase from $47.8 million in Q1 2019, representing 83% of total revenue [19] - Revenue from Surgical & Sports Medicine products was $10.4 million, a 13% increase from $9.3 million in Q1 2019, representing 17% of total revenue [20] - Revenue from PuraPly products was $32.5 million, a 28% increase from $25.4 million in Q1 2019, accounting for approximately 53% of total revenue [21] Market Data and Key Metrics Changes - Sales through February 2020 were up 13% year-over-year, but sales declined 14% year-over-year in the second half of March due to COVID-19 disruptions [11] - Sales of Surgical & Sports Medicine products declined 52% year-over-year in April, while Advanced Wound Care products saw a 24% decline [13] Company Strategy and Development Direction - The company is focused on long-term growth and market share gain, driven by investments in the commercial team and new product launches [38] - The strategy includes expanding the office presence for PuraPly and adapting to the shift of procedures from outpatient settings to offices [64] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about recovery trends as healthcare facilities begin to reopen, but acknowledged uncertainty regarding the pace of recovery [14] - The company expects to realize $5 million to $6 million in savings in Q2 2020 due to proactive cost-saving measures [29] Other Important Information - The company withdrew its fiscal year 2020 revenue guidance due to uncertainties from the COVID-19 pandemic [36] - As of March 31, 2020, the company had $46.9 million in cash and $110 million in debt obligations [34] Q&A Session Summary Question: Insights on recovery signs across product lines and geographies - Management noted that capacity for Surgical & Sports Medicine has opened up to 80%-82%, with rural hospitals showing better performance [42] - Wound care centers are gradually reopening, with 80% now open and more than half accepting new patients [44] Question: Impact of deferred procedures on product mix - Management indicated that larger and more infected wounds are being observed, leading to expected increases in PuraPly sales [50] Question: Percentage of business related to traumatic wounds - Management stated that 45% of procedures are nonelective, with a reasonable percentage being traumatic, but specific percentages were not disclosed [53] Question: Expectations for backlog recovery - Management anticipates that about 85% of the backlog will be addressed within 4 to 5 months [55] Question: Criteria for allowing sales reps into centers - The criteria depend on regional COVID-19 experiences, with varying rates of access for sales reps [58] Question: Importance of clinical data presentations - Management expressed concern over the inability to present clinical data at conferences due to the pandemic, which may impact brand support [66]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organi ...

Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2019 Earnings Conference Call March 9, 2020 5:00 PM ET Company Participants Gary S. Gillheeney, Sr. - President & Chief Executive Officer Tim Cunningham - Chief Financial Officer Conference Call Participants Matt Miksic - Credit Suisse Richard Newitter - SVB Leerink Ryan Zimmerman - BTIG Steven Lichtman - Oppenheimer & Company Operator Good afternoon, ladies and gentlemen, and welcome to the Fourth Quarter 2019 Earnings Conference Call for Organogenesis Holdings ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in Its Charter) Delaware 98-1329150 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 85 ...

Organogenesis Holdings Inc. (NASDAQ:ORGO) Q3 2019 Earnings Conference Call November 12, 2019 5:00 PM ET Company Participants Gary Gillheeney - President & Chief Executive Officer Tim Cunningham - Chief Financial Officer Conference Call Participants Vik Chopra - Credit Suisse Ryan Zimmerman - BTIG Steven Lichtman - Oppenheimer & Company Operator Good afternoon, ladies and gentlemen, and welcome to the Third Quarter 2019 Earnings Conference Call for Organogenesis Holdings Incorporated. At this time, all parti ...